Expert Review of Clinical Pharmacology最新文献_第9页

New and emerging treatments for vitiligo: a narrative review. 新的和新兴的治疗白癜风：叙述回顾。

IF 3.6 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2026-01-01 Epub Date: 2026-02-06 DOI: 10.1080/17512433.2026.2626458

Carolina Rodrigues Mendonça, Adam Mohamed, Amir Mohamed, Cesar Ferreira, Tiago Torres

{"title":"New and emerging treatments for vitiligo: a narrative review.","authors":"Carolina Rodrigues Mendonça, Adam Mohamed, Amir Mohamed, Cesar Ferreira, Tiago Torres","doi":"10.1080/17512433.2026.2626458","DOIUrl":"10.1080/17512433.2026.2626458","url":null,"abstract":"Introduction: Vitiligo is a chronic autoimmune skin disorder characterized by progressive melanocyte loss, resulting in well-demarcated depigmented patches that significantly impact quality of life. Affecting 0.5-2% of the global population, vitiligo poses both psychosocial and therapeutic challenges. Despite multiple conventional therapies such as corticosteroids, calcineurin inhibitors, and phototherapy, durable repigmentation remains difficult to achieve.Areas covered: This review summarizes recent advances in understanding the emerging medical treatment of vitiligo. A targeted literature search was conducted using PubMed, Embase, and ClinicalTrials.gov from inception to April 2025. Key clinical trial data are discussed to evaluate efficacy, safety and durability of response across therapeutic classes.Expert opinion: The approval of topical ruxolitinib marks a pivotal step toward precision therapy in vitiligo. Ongoing studies of combination and maintenance regimens offer promise for sustained repigmentation and disease stabilization. However, optimizing long-term outcomes requires continued translational research to elucidate mechanisms of relapse, improve accessibility of emerging therapies and personalize treatment strategies to individual disease phenotypes.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"117-132"},"PeriodicalIF":3.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146124296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Chelating anticoagulants reduce plasma doxycycline measurements: implications for doxy PEP monitoring. 螯合抗凝剂减少血浆强力霉素测量：对强力霉素PEP监测的影响。

IF 3.6 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2026-01-01 Epub Date: 2026-02-19 DOI: 10.1080/17512433.2026.2632931

Michele B Daly, Micah Spandau, Tiancheng E Edwards, Chuong Dinh, Jeffrey Fountain, Jeannette A Dienhart, Christopher Conway-Washington, Colleen Kelley, Walid Heneine, Richard Haaland

{"title":"Chelating anticoagulants reduce plasma doxycycline measurements: implications for doxy PEP monitoring.","authors":"Michele B Daly, Micah Spandau, Tiancheng E Edwards, Chuong Dinh, Jeffrey Fountain, Jeannette A Dienhart, Christopher Conway-Washington, Colleen Kelley, Walid Heneine, Richard Haaland","doi":"10.1080/17512433.2026.2632931","DOIUrl":"10.1080/17512433.2026.2632931","url":null,"abstract":"Background: Doxycycline post-exposure prophylaxis is recommended for men who have sex with men at high risk for sexually transmitted infections. Accurate doxycycline measures ensure consistent evaluation of adherence and efficacy.Research design and methods: Participants received 200 mg doxycycline (blood collected in citrate [n = 20] or heparin [n = 14] tubes). Ex vivo analyses compared exogenous doxycycline spiked into blood from matched donors collected in citrate and heparin (n = 8) or EDTA and heparin (n = 9). Plasma doxycycline was quantified with liquid chromatography-tandem mass spectrometry and reported as geometric mean [95% CI].Results: After dosing, plasma doxycycline AUC24-72 h from citrate blood (17.07 µg/mL*hr [13.89-20.99]) was 3-times lower than heparin blood (54.57 [44.18-67.40]). Similarly, reduced plasma doxycycline was observed when drug was spiked into citrate (0.062 µg/mL [0.059-0.065]) versus heparin blood (0.084 µg/mL [0.077-0.092]) from matched donors (p = 0.0002). EDTA blood, also showed significantly lower plasma doxycycline (0.052 µg/mL [0.049-0.054]) than heparin blood (0.078 µg/mL [0.071-0.084]) (p < 0.0001).Conclusions: Chelating anticoagulants significantly reduce plasma doxycycline concentrations, likely through disruption of doxycycline-metal ion complexes and increased drug partitioning in red blood cells. Pharmacologically focused doxycycline research should prioritize blood collection in non-chelating anticoagulants or apply a correction factor if chelating anticoagulants are used.Clinical trial registration: NCT04860505, NCT05853120, and NCT06545656.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"199-205"},"PeriodicalIF":3.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146212722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Risk factors and clinical outcomes associated with mitral annular calcification in hypertrophic obstructive cardiomyopathy: a retrospective analysis. 肥厚性梗阻性心肌病二尖瓣环钙化相关的危险因素和临床结果：回顾性分析。

IF 3.6 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2026-01-01 Epub Date: 2026-02-12 DOI: 10.1080/17512433.2026.2619131

Bowen Guo, Bangrong Song, Xiaoyu Xu, Haiming Dang, Ran Dong

{"title":"Risk factors and clinical outcomes associated with mitral annular calcification in hypertrophic obstructive cardiomyopathy: a retrospective analysis.","authors":"Bowen Guo, Bangrong Song, Xiaoyu Xu, Haiming Dang, Ran Dong","doi":"10.1080/17512433.2026.2619131","DOIUrl":"10.1080/17512433.2026.2619131","url":null,"abstract":"Objective: This study aimed to identify risk factors associated with mitral annular calcification (MAC) in patients with hypertrophic obstructive cardiomyopathy (HOCM) and to evaluate its relationship with clinical outcomes.Methods: A total of 310 patients with HOCM who underwent interventricular septal myectomy were retrospectively analyzed. Patients were divided into a MAC group (n = 24) and a non-MAC group (n = 286). Demographic characteristics, echocardiographic parameters, and clinical data were compared between groups. Major adverse cardiovascular and cerebrovascular event (MACCE) and circulating levels of brain natriuretic peptide, Apelin, and Galectin-3 were analyzed.Results: Patients with MAC were older and showed higher prevalence of aortic annular calcification, mitral leaflet thickening, and moderate-to-severe tricuspid regurgitation (P < 0.05). Multivariate analysis identified gender, age, aortic annular calcification, moderate-to-severe tricuspid regurgitation, and mitral leaflet thickening as independent risk factors for MAC. Patients with MAC showed larger left ventricular end-diastolic volume, reduced left ventricular ejection fraction, and greater left atrium mass, and a higher incidence of MACCE than those without MAC (P < 0.05).Conclusion: In HOCM undergoing septal myectomy, MAC is associated with adverse cardiac remodeling and unfavorable clinical outcomes. Identification of related factors may aid risk stratification and perioperative management.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"45-53"},"PeriodicalIF":3.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145988908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The pharmacology and clinical evidence for the use of dual versus single antiplatelet therapy. 双重抗血小板治疗与单一抗血小板治疗的药理学和临床证据。

IF 3 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2026-01-01 Epub Date: 2026-01-09 DOI: 10.1080/17512433.2026.2612770

Claudio Laudani, Luis Ortega-Paz, Francesco Franchi, Fabiana Rollini, Ali Zgheib, Georges El Khoury, Maryam Farahmandsadr, Mohmmad Alawajneh, Marco Spagnolo, Giovanni Occhipinti, Davide Capodanno, Dominick J Angiolillo

{"title":"The pharmacology and clinical evidence for the use of dual versus single antiplatelet therapy.","authors":"Claudio Laudani, Luis Ortega-Paz, Francesco Franchi, Fabiana Rollini, Ali Zgheib, Georges El Khoury, Maryam Farahmandsadr, Mohmmad Alawajneh, Marco Spagnolo, Giovanni Occhipinti, Davide Capodanno, Dominick J Angiolillo","doi":"10.1080/17512433.2026.2612770","DOIUrl":"10.1080/17512433.2026.2612770","url":null,"abstract":"Introduction: In patients with coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI), long-term dual antiplatelet therapy (DAPT) is the current standard of care. However, recent evidence suggests that shortening DAPT duration in favor of single antiplatelet therapy (SAPT) can optimize the overall clinical benefit, as it can prevent bleeding without significant tradeoff in ischemic events.Areas covered: In this narrative review, we synthesize current evidence from PubMed and SCOPUS on SAPT vs DAPT regimens in CAD patients undergoing PCI, including pharmacodynamic and clinical outcomes data, and we propose an algorithm for appropriate antiplatelet regimen selection depending on the ischemic and bleeding risk profile of the individual patient.Expert opinion: The landscape of antiplatelet treatment regimens has significantly evolved over time, with the current trend being toward a tailored approach based on risk profile, aiming to reduce the risk of bleeding while maintaining ischemic protection. The accurate evaluation of each patient's ischemic and bleeding risk profile is of utmost importance. Dedicated tools have been developed to optimize patient risk profiling and help guide the selection of the antiplatelet regimen. Based on risk estimation, several strategies can be used to reduce the overall risk, including the selection and duration of the antiplatelet regimen.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"27-44"},"PeriodicalIF":3.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145911309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An update on the treatment paradigm for non-clear cell renal cell carcinoma. 非透明细胞肾细胞癌治疗模式的最新进展。

IF 3.6 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2026-01-01 Epub Date: 2026-01-13 DOI: 10.1080/17512433.2026.2615995

Alessandro Rametta, Noemi Crippa, Simone Rota, Eleonora Gusmaroli, Marco Stellato, Elena Verzoni, Amedeo Nuzzo, Melanie Claps, Valentina Guadalupi, Giuseppe Procopio

{"title":"An update on the treatment paradigm for non-clear cell renal cell carcinoma.","authors":"Alessandro Rametta, Noemi Crippa, Simone Rota, Eleonora Gusmaroli, Marco Stellato, Elena Verzoni, Amedeo Nuzzo, Melanie Claps, Valentina Guadalupi, Giuseppe Procopio","doi":"10.1080/17512433.2026.2615995","DOIUrl":"10.1080/17512433.2026.2615995","url":null,"abstract":"Introduction: Non - clear cell renal cell carcinoma (nccRCC) encompasses a heterogeneous group of rare malignancies, representing approximately 20-25% of all renal cancers. Unlike clear cell RCC (ccRCC), these subtypes - papillary, chromophobe, collecting duct, translocation, molecularly defined variants and others - display distinct biological behaviors, genetic profiles, and therapeutic sensitivities, which preclude a uniform treatment approach.Areas covered: This review provides an updated overview of systemic therapy for nccRCC, integrating evidence from prospective trials, retrospective series, and translational research. For most of these histologies, immune checkpoint inhibitor (ICI) - based combinations (e.g. pembrolizumab - lenvatinib, nivolumab - cabozantinib or nivolumab-ipilimumab) have demonstrated the best activity. In chromophobe RCC (chRCC), also mechanistic target of rapamycin (mTOR) inhibition appears particularly relevant, whereas in collecting duct carcinoma and renal medullary carcinoma platinum-based chemotherapy continue to have an important role, with cabozantinib showing encouraging results. Novel biomarker-driven approaches are emerging for selected molecular subsets.Expert opinion: Although remarkable progress has been achieved, the optimal therapeutic strategy for nccRCC remains undefined. Future efforts should focus on histology- and biomarker-driven clinical trials, molecular stratification, to optimize efficacy across subtypes. International collaboration is crucial to overcome the challenges posed by the rarity and biological heterogeneity of these tumors.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"5-16"},"PeriodicalIF":3.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145943033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Vaping Δ⁹-tetrahydrocannabinol (Δ⁹-THC) in liquid forms: pharmacokinetics, pharmacodynamics, and regulatory implications. 液体形式的电子烟Δ9-Tetrahydrocannabinol （Δ9-THC）：药代动力学、药效学和监管意义。

IF 3.6 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2026-01-01 Epub Date: 2026-02-16 DOI: 10.1080/17512433.2026.2630756

Ashleigh C Block, Danielle M Smith, Maciej L Goniewicz

{"title":"Vaping Δ9-tetrahydrocannabinol (Δ9-THC) in liquid forms: pharmacokinetics, pharmacodynamics, and regulatory implications.","authors":"Ashleigh C Block, Danielle M Smith, Maciej L Goniewicz","doi":"10.1080/17512433.2026.2630756","DOIUrl":"10.1080/17512433.2026.2630756","url":null,"abstract":"Introduction: Little is known about the pharmacokinetics (PK) and pharmacodynamics (PD) of Δ9-tetrahydrocannabinol (Δ9-THC) when vaped in liquid formulations. As the prevalence of vaping Δ9-THC in liquid forms grows, understanding the factors that influence PK/PD profiles is critical to guide future research and cannabis regulation.Areas covered: Currently, no human studies have elucidated the PK/PD profile of Δ9-THC from vaped liquids, as confirmed by searches of PubMed and Embase. Using existing research on smoked cannabis and nicotine-containing e-cigarettes, this review examines the potential influence of product potency, vaporization efficiency, consumer use behaviors, aerosol bioavailability, and other constituents on the PK/PD profile of Δ9-THC vaped in liquid forms. Further, we hypothesize whether PK/PD of Δ9-THC in liquid forms may differ from smoked cannabis and address potential regulatory implications (United States-focused) of novel vaping products.Expert opinion: While more potent than smoked cannabis, vaped liquid formulations with Δ9-THC may have a similar PK/PD profile through modulation of Δ9-THC delivery by consumer use behaviors. Potential health effects of high-potency vaping products with Δ9-THC in liquid form need to be carefully studied. Lastly, researchers should continue to think creatively about how this important work can progress, while restrictions on Δ9-THC continue to hinder research.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"175-190"},"PeriodicalIF":3.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13251897/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146149561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Understanding RAMP1's role in hormonal migraine may improve CGRP-targeted therapies. 了解RAMP1在激素偏头痛中的作用可能会改善cgrp靶向治疗。

IF 3 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2026-01-01 Epub Date: 2026-02-02 DOI: 10.1080/17512433.2026.2624476

Lars Edvinsson, Anja Holm

引用次数: 0

Therapeutic drug monitoring for de-escalating anti-tumor necrosis factor therapy in patients with inflammatory bowel disease. 炎症性肠病患者抗肿瘤坏死因子治疗降糖的药物监测。

IF 3.6 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2026-01-01 Epub Date: 2026-02-16 DOI: 10.1080/17512433.2026.2630758

Ajay Gade, Alessandra Saraga, Alfonso Elosua, Antony Ishan, Tina Deyhim, Nathan David Vanshelboym Rothschild, Adam S Cheifetz, Konstantinos Papamichael

{"title":"Therapeutic drug monitoring for de-escalating anti-tumor necrosis factor therapy in patients with inflammatory bowel disease.","authors":"Ajay Gade, Alessandra Saraga, Alfonso Elosua, Antony Ishan, Tina Deyhim, Nathan David Vanshelboym Rothschild, Adam S Cheifetz, Konstantinos Papamichael","doi":"10.1080/17512433.2026.2630758","DOIUrl":"10.1080/17512433.2026.2630758","url":null,"abstract":"Introduction: Cumulative evidence suggests that proactive therapeutic drug monitoring (TDM) of anti-tumor necrosis factor (anti-TNF) therapy is associated with favorable outcomes in inflammatory bowel disease (IBD). However, there is limited information regarding the role of proactive TDM for de-escalating anti-TNF therapy in IBD.Areas covered: This narrative review will provide an overview of the role of proactive TDM for anti-TNF therapy de-escalation in IBD. A literature search was performed using PubMed between 2005 and June 2025.Expert opinion: Cumulative evidence suggests that proactive TDM plays a key role in guiding anti-TNF therapy de-escalation, as in patients with supra-therapeutic drug concentrations and discontinuation of the IMM in case of combination therapy with infliximab, as in patients with high drug concentrations prior to IMM withdrawal. Moreover, preliminary data suggest that proactive TDM may also help guiding anti-TNF therapy withdrawal, as in patients with sustained remission and undetectable or low drug concentrations at the time of drug discontinuation. Finally, proactive TDM is also important for surveillance of patients after treatment de-escalation to prevent low drug concentrations and immunogenicity. However, there are still some knowledge gaps including the ideal drug concentration before treatment de-escalation and if drug clearance rather than concentration can better guide anti-TNF therapy de-escalation.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"167-174"},"PeriodicalIF":3.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146164710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Population pharmacokinetic modeling of piperacillin in critically ill adult patients: consideration of sex-based differences during model development. 危重成人患者哌拉西林的群体药代动力学建模：模型开发过程中基于性别差异的考虑

IF 3.6 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2026-01-01 Epub Date: 2026-01-30 DOI: 10.1080/17512433.2026.2620530

Ibrahim El-Haffaf, David Williamson, Van Dong Nguyen, Alexandre Duong, Virginie Williams, Marc-André Smith, Martin Albert, Hugues Blain, Nicolas Goettel, Bianca Beloin-Jubinville, François Lamontagne, Amélie Marsot

{"title":"Population pharmacokinetic modeling of piperacillin in critically ill adult patients: consideration of sex-based differences during model development.","authors":"Ibrahim El-Haffaf, David Williamson, Van Dong Nguyen, Alexandre Duong, Virginie Williams, Marc-André Smith, Martin Albert, Hugues Blain, Nicolas Goettel, Bianca Beloin-Jubinville, François Lamontagne, Amélie Marsot","doi":"10.1080/17512433.2026.2620530","DOIUrl":"10.1080/17512433.2026.2620530","url":null,"abstract":"Background: Piperacillin population pharmacokinetic models reportedly perform poorly for critically ill females compared to males. We aimed to explore potential methods that may better adjust for female data during model development.Research design and methods: Total piperacillin concentrations were used from a prospective observational study in NONMEM v7.5.1. Two models were developed following different approaches: classic stepwise approach and sex-specific approach. Relationship between covariates and estimated parameters were explored by statistically and graphically assessing their performance on males and females separately. Dosing regimen simulations were also performed separately by sex.Results: A one-compartment model based on data from 70 critically ill patients (49/21 males/females) with 233 concentrations best fit the data with both approaches. Creatinine clearance was the most significant covariate for the classic approach model, while creatinine clearance was best for male patients and estimated glomerular filtration rate was best for female patients with the sex-specific approach. Dosing recommendations were different between male and female patients with the sex-specific model.Conclusion: This study is the first to consider sex-specific covariates during the modeling process for piperacillin in critically ill patients. This approach may help reduce differences in model predictions between males and females in model-informed precision dosing strategies.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"69-83"},"PeriodicalIF":3.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146009605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Review of anti-amyloid-beta (Aβ) monoclonal antibodies for the treatment of Alzheimer's disease. 抗淀粉样蛋白β (Aβ)单克隆抗体治疗阿尔茨海默病的研究进展

IF 3 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2025-12-01 Epub Date: 2025-09-22 DOI: 10.1080/17512433.2025.2556122

Emily Francis, Samantha Paylor, Cindy Van, Bindu Mathews, Millad J Sobhanian, Daniel Z Mansour, George Hennawi, Nicole J Brandt

{"title":"Review of anti-amyloid-beta (Aβ) monoclonal antibodies for the treatment of Alzheimer's disease.","authors":"Emily Francis, Samantha Paylor, Cindy Van, Bindu Mathews, Millad J Sobhanian, Daniel Z Mansour, George Hennawi, Nicole J Brandt","doi":"10.1080/17512433.2025.2556122","DOIUrl":"10.1080/17512433.2025.2556122","url":null,"abstract":"Introduction: Alzheimer's disease (AD) remains a major public health challenge, with growing prevalence and limited treatment options that modify disease progression. Recent advances have led to the development and approval of Anti-amyloid-β (Aβ) monoclonal antibodies, which represent a paradigm shift from symptomatic management to targeted disease modification.Areas ccovered: Agents such as lecanemab and donanemab selectively bind aggregated forms of Aβ and have demonstrated modest but statistically significant slowing of cognitive and functional decline in early AD. However, these therapies are associated with amyloid-related imaging abnormalities (ARIA), particularly in individuals carrying the APOE ε4 allele, necessitating close monitoring and individualized risk assessment. Implementation challenges, including high treatment burden, cost, and real-world applicability, have limited broad clinical adoption. This review examines the mechanistic differences, clinical trial outcomes, and safety considerations of Aβ monoclonal antibodies, while also highlighting emerging therapies and the need for inclusive, precision-guided approaches.Expert opinion: As research continues to evolve, balancing clinical benefits with safety and accessibility will be critical in defining the role of anti-amyloid-β therapies within the broader landscape of AD care.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"1063-1078"},"PeriodicalIF":3.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145052654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0